Moreover, figitumumab, another mAb directed against IGF1R, has shown preliminary encouraging results in a phase II trial in patients with ES, particularly when elevated blood IGF-1 levels were detected at the baseline. This evidence concerns the gene IGF1R and Ewing sarcoma.